GLP-1 agonists have become the dominant spend catalyst, with class spending ~$132B and growth contribution approaching ...

Shareholder approval positions Garijo to steer strategy toward operational rigor, portfolio discipline, and more consistent ...

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...

Teva will pay $700 million upfront plus $200 million in commercial milestones, along with royalties on global net sales, with ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often ...

In the first part of his interview, Jeff Golfman, notes how The Strait of Hormuz disruption exposes broader global supply chain contraction, raising risks for vaccines, cancer therapies, and other ...

In a conversation with Pharmaceutical Executive at Asembia’s AXS26 Summit, Kim Plesnarski, vice president, strategic market ...

In today's Pharmaceutical Executive Daily, Rocket Pharmaceuticals announces a $180 million sale of its rare pediatric disease priority review voucher, Teva Pharmaceutical enters a definitive agreement ...

Rare Pediatric Disease PRVs can accelerate FDA review timelines for another asset, and their resale market creates a tangible ...

In the first part of his interview, Jeff Golfman, notes how The Strait of Hormuz disruption exposes broader global supply ...

In a conversation with Pharmaceutical Executive at Asembia’s AXS26 Summit, Kim Plesnarski, vice president, strategic market ...